How to Reconstitute Peptides: BAC Water, Syringes & Safety Guide

Lyophilization is not drying in the household sense. The material is frozen, the ice is removed under vacuum by sublimation, and residual bound water is pulled off in a second drying step. Each stage applies stress to the peptide, and the stress does not always leave the molecule as it found it.

The clearest published example comes from teriparatide, the 34-residue parathyroid hormone fragment PTH(1-34). A study in European Journal of Pharmaceutics and Biopharmaceutics in 2016 compared lyophilized material with solutions that had never been frozen. The dry formulations were stable for months. After reconstitution the picture inverted: physical stability varied considerably with peptide concentration and storage temperature, and precipitation appeared within two to four weeks in some samples. The samples that had never been lyophilized showed no precipitation at all over twelve weeks in the liquid state.

The authors attributed the difference to a higher-order structure that is perturbed by the combined stress of freezing and drying, which leaves the peptide more prone to aggregate once it is back in solution. The effect was worse at higher peptide concentrations and at higher temperatures. Critically, the precipitation correlated with rising counts of subvisible particles, meaning the damage begins before anything is visible to the eye.

Why this matters: a purity figure on a certificate of analysis describes the powder that was tested, not how that powder behaves once dissolved. Two vials with identical 99 percent HPLC results can diverge in solution because of moisture content, buffer or counterion, without either lab making a mistake.

The diluent question usually gets reduced to a slogan: bacteriostatic water for multi-use vials, sterile water for single use. That is directionally correct and incomplete, because the USP label for Bacteriostatic Water for Injection carries restrictions that rarely reach vendor instructions.

The preparation is water for injection with 0.9 percent (9 mg per mL) or 1.1 percent (11 mg per mL) benzyl alcohol as the preservative, supplied in a multiple-dose container intended for repeated withdrawals. Its stated pH is 5.7, with a permitted range of 4.5 to 7.0. The label also states that the preparation must be made approximately isotonic before use, that intravenous administration without a solute may cause hemolysis, and that it must not be used in neonates, for fluid replacement, or in epidural or spinal procedures.

Two consequences follow. First, bacteriostatic water is not a physiological diluent. It is hypotonic water with a preservative, and the label itself says the osmolarity has to be corrected by whatever is added to it. Bacteriostatic saline, 0.9 percent sodium chloride with the same preservative, is the conventional choice where tonicity matters. Second, the preservative is a chemical actor, not an inert passenger. A 2015 study in the Journal of Pharmaceutical Sciences showed that benzyl alcohol induces aggregation of interferon alfa-2a in a concentration-dependent manner, by populating a partially unfolded intermediate rather than unfolding the whole protein. A 2023 review in Pharmaceutics describes the same pattern across biologics. Preservative effects are also compound-specific: a 2025 paper in Molecular Pharmaceutics found benzyl alcohol did not perturb the model peptide it tested while phenol did. The point is not that bacteriostatic water ruins peptides. The interaction is real, documented, and essentially never characterised for research peptides sold without a formulation dossier.

The microbiological side of the trade-off is where the practical rules come from. CDC injection safety guidance is unambiguous: needles and syringes are single use, and a vial must never be entered with a syringe that has already been used. Once a multi-dose vial is punctured it is dated and discarded within 28 days unless the manufacturer specifies otherwise. Note the structure of that rule. The 28 days is a contamination window, not a stability data point, and it can easily be longer than the chemical stability of the compound inside it. Where two windows exist, the shorter one governs.

A U-100 insulin syringe is calibrated for a solution containing 100 units per millilitre, so 100 units equals 1 mL and one unit equals 0.01 mL. The word unit refers to the insulin scale printed on the barrel, not to the peptide inside. Every calculation runs through concentration:

• concentration in mg per mL = peptide mass in mg divided by diluent volume in mL
• units to draw = target dose in mg divided by concentration in mg per mL, multiplied by 100

One implication gets lost constantly. Adding more water does not create more material. The mass in the vial is fixed when it is filled, so a larger diluent volume spreads the same peptide across more liquid, and more volume must be drawn for the same dose. The number of doses does not change.

The classic instruction is to run the diluent down the inner wall and swirl rather than shake. The reason usually given, mechanical shear destroying the peptide, is the weakest version of the argument. The pathways that have actually been measured matter more.

Freezing and thawing. A 2026 study in the Journal of Pharmaceutical Sciences took human growth hormone solutions through freeze and thaw cycles and frozen storage at minus 40 degrees Celsius. Substantial aggregation occurred on freezing, and destabilisation was dominated by interfacial stresses generated during freezing rather than by dissolved oxygen. Freezing a reconstituted solution does not preserve it. It adds a stress event every time the material is thawed and refrozen.

Water and temperature in the dry state. A 1994 paper in Pharmaceutical Research showed that lyophilized insulin aggregates when exposed to elevated temperature and moisture, that the extent of aggregation correlated directly with water uptake by the powder, and that alkaline media accelerated the process. For storage that argues for a sealed vial, desiccant, a freezer, and letting the vial reach room temperature before opening so condensation does not form on the cake.

Solution pH. In the bivalirudin storage study from 2017, aqueous solutions of the 20-residue peptide were most stable between apparent pH 3 and 4, and the researchers noted that bivalirudin in the commercially reconstituted product was long-term unstable. The lesson is structural: the pH of your solution is set by the diluent and whatever else is in the vial, not by the peptide label, and bacteriostatic water ships anywhere between pH 4.5 and 7.0.

Adsorption to surfaces. This is the most under-discussed failure mode in peptide work. A 2011 study in Analytical Biochemistry measured recovery of radiolabelled peptides, including ghrelin, GLP-1, insulin and peptide YY, from a range of glass and plastic containers over 48 hours. Recovery varied substantially between containers and between peptides. Siliconised surfaces reduced binding, and adding 1 percent bovine serum albumin improved recovery, with more than 89 percent recovery for all tested peptides in the best-matched containers. A dilute peptide solution can therefore lose a meaningful fraction of its content to the vial wall, the syringe barrel or the tubing before it reaches an assay. If a measurement comes back low, adsorption belongs on the list of explanations next to degradation, and the prevention is the same as the fix: do not dilute beyond what the protocol needs.

What a compromised solution looks like. Cloudiness, particles, gel-like stringing or unexpected colour are late signals. Subvisible particle counts rose before precipitation became visible in the teriparatide work, which is the argument for a fixed in-solution window rather than judging by eye.

• The 21 and 28 day figures are conventions. The 28 days is a multi-dose vial contamination window from injection safety policy, and the shorter windows quoted per compound come from vendor profiles rather than published stability studies. For most research peptides, nobody has measured the in-solution stability of the material in your hands.
• The published reconstitution data belong to pharmaceutical development. Teriparatide and bivalirudin were studied as commercial products with defined buffers, excipients and fill volumes. That data shows what can happen to a peptide after lyophilization. It does not transfer as a number to an unrelated compound from a research vendor.
• Purity is not stability. An HPLC purity figure says nothing about residual moisture, counterion content or aggregation propensity after dissolution, and those variables drove the outcomes in the studies above.
• Sterility rests entirely on technique. Research peptides are laboratory materials, not licensed sterile medicines. Single use needles and syringes, no re-entry with a used syringe, and disposal of single-dose containers after one withdrawal are the controls these rules were written for.

Reconstitution is treated as a step you complete at the start of an experiment. It is closer to a set of decisions that quietly set the ceiling on everything that follows. Before any of them matter, the powder has to be what the label claims, which is the subject of our COA red flags report.